JT 05 - JYANT TechnologiesAlternative Names: JT05
Latest Information Update: 11 Aug 2016
At a glance
- Originator JYANT Technologies
- Class Antibodies
- Mechanism of Action CXC chemokine inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Aug 2016 Preclinical trials in Solid tumours in USA (unspecified route)